Resources from the same session
LBA1 - A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3
Presenter: Silke Gillessen
Session: Presidential Symposium I: Practice-changing trials
Resources:
Abstract
Slides
Webcast
LBA2 - POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (c-p) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy (Chemo)
Presenter: Sheela Rao
Session: Presidential Symposium I: Practice-changing trials
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA2
Presenter: Dominik Modest
Session: Presidential Symposium I: Practice-changing trials
Resources:
Slides
Webcast
709O - Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Presenter: Domenica Lorusso
Session: Presidential Symposium I: Practice-changing trials
Resources:
Abstract
Slides
Webcast
Invited Discussant 709O
Presenter: Remy Nout
Session: Presidential Symposium I: Practice-changing trials
Resources:
Slides
Webcast
LBA3 - Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study
Presenter: Josep Llovet
Session: Presidential Symposium I: Practice-changing trials
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA3
Presenter: Angela Lamarca
Session: Presidential Symposium I: Practice-changing trials
Resources:
Slides
Webcast
Q&A and discussion
Session: Presidential Symposium I: Practice-changing trials
Resources:
Webcast